Panion & BF Biotech Inc
Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, provides western medicines, cosmetics, testing reagents, food and chemical products in Taiwan, the United States, China, Hong Kong, Macau, and internationally. The company offers products in the areas of antibody, respiratory, gastrointestinal, COVID-19 IVD, antigen, anti-aging, active pharmaceutical ingredients, disease treatment,… Read more
Panion & BF Biotech Inc (1760) - Net Assets
Latest net assets as of September 2025: NT$1.90 Billion TWD
Based on the latest financial reports, Panion & BF Biotech Inc (1760) has net assets worth NT$1.90 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.12 Billion) and total liabilities (NT$1.22 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.90 Billion |
| % of Total Assets | 60.87% |
| Annual Growth Rate | 12.59% |
| 5-Year Change | 55.02% |
| 10-Year Change | 148.01% |
| Growth Volatility | 37.71 |
Panion & BF Biotech Inc - Net Assets Trend (2009–2024)
This chart illustrates how Panion & BF Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Panion & BF Biotech Inc (2009–2024)
The table below shows the annual net assets of Panion & BF Biotech Inc from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.92 Billion | +0.58% |
| 2023-12-31 | NT$1.91 Billion | -4.78% |
| 2022-12-31 | NT$2.01 Billion | +3.83% |
| 2021-12-31 | NT$1.93 Billion | +55.89% |
| 2020-12-31 | NT$1.24 Billion | -8.80% |
| 2019-12-31 | NT$1.36 Billion | +0.67% |
| 2018-12-31 | NT$1.35 Billion | +61.69% |
| 2017-12-31 | NT$835.25 Million | +3.58% |
| 2016-12-31 | NT$806.41 Million | +4.05% |
| 2015-12-31 | NT$775.03 Million | +9.03% |
| 2014-12-31 | NT$710.84 Million | +8.27% |
| 2013-12-31 | NT$656.55 Million | +135.44% |
| 2012-12-31 | NT$278.86 Million | -6.10% |
| 2011-12-31 | NT$296.98 Million | -1.54% |
| 2010-12-31 | NT$301.62 Million | -7.08% |
| 2009-12-31 | NT$324.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Panion & BF Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 26784100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$134.98 Million | 7.02% |
| Common Stock | NT$857.39 Million | 44.61% |
| Other Comprehensive Income | NT$128.42 Million | 6.68% |
| Other Components | NT$801.39 Million | 41.69% |
| Total Equity | NT$1.92 Billion | 100.00% |
Panion & BF Biotech Inc Competitors by Market Cap
The table below lists competitors of Panion & BF Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhongjie (Jiangsu) Technology Co.Ltd.
SHE:301072
|
$122.30 Million |
|
Namhae Chemical
KO:025860
|
$122.35 Million |
|
Aimei Health Technology Co., Ltd Ordinary Share
NASDAQ:AFJK
|
$122.36 Million |
|
Allied Energy Inc
PINK:AGGI
|
$122.37 Million |
|
Sern Kou Resources Bhd
KLSE:7180
|
$122.21 Million |
|
Zhejiang XinNong Chemical Co Ltd Class A
SHE:002942
|
$122.21 Million |
|
Context Therapeutics Inc
NASDAQ:CNTX
|
$122.17 Million |
|
Changshu Tongrun Auto
SHG:603201
|
$122.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Panion & BF Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,911,080,000 to 1,922,180,000, a change of 11,100,000 (0.6%).
- Net income of 124,523,000 contributed positively to equity growth.
- Dividend payments of 128,609,000 reduced retained earnings.
- Other comprehensive income increased equity by 16,394,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$124.52 Million | +6.48% |
| Dividends Paid | NT$128.61 Million | -6.69% |
| Other Comprehensive Income | NT$16.39 Million | +0.85% |
| Other Changes | NT$-1.21 Million | -0.06% |
| Total Change | NT$- | 0.58% |
Book Value vs Market Value Analysis
This analysis compares Panion & BF Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.71x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.58x to 2.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$5.74 | NT$60.70 | x |
| 2010-12-31 | NT$5.06 | NT$60.70 | x |
| 2011-12-31 | NT$5.10 | NT$60.70 | x |
| 2012-12-31 | NT$5.12 | NT$60.70 | x |
| 2013-12-31 | NT$10.66 | NT$60.70 | x |
| 2014-12-31 | NT$10.27 | NT$60.70 | x |
| 2015-12-31 | NT$11.21 | NT$60.70 | x |
| 2016-12-31 | NT$11.64 | NT$60.70 | x |
| 2017-12-31 | NT$12.06 | NT$60.70 | x |
| 2018-12-31 | NT$17.41 | NT$60.70 | x |
| 2019-12-31 | NT$17.44 | NT$60.70 | x |
| 2020-12-31 | NT$15.91 | NT$60.70 | x |
| 2021-12-31 | NT$24.40 | NT$60.70 | x |
| 2022-12-31 | NT$23.39 | NT$60.70 | x |
| 2023-12-31 | NT$22.28 | NT$60.70 | x |
| 2024-12-31 | NT$22.40 | NT$60.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Panion & BF Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.48%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.14%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.67x
- Recent ROE (6.48%) is above the historical average (3.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 1.74% | 0.91% | 0.64x | 2.98x | NT$-24.21 Million |
| 2010 | -13.80% | -7.49% | 0.61x | 3.03x | NT$-67.78 Million |
| 2011 | -12.53% | -6.21% | 0.63x | 3.23x | NT$-65.20 Million |
| 2012 | -14.89% | -6.01% | 0.73x | 3.39x | NT$-67.81 Million |
| 2013 | 2.76% | 2.12% | 0.86x | 1.52x | NT$-47.51 Million |
| 2014 | 6.79% | 4.76% | 0.92x | 1.56x | NT$-22.82 Million |
| 2015 | 9.42% | 6.06% | 1.03x | 1.52x | NT$-4.51 Million |
| 2016 | 11.13% | 8.55% | 0.88x | 1.48x | NT$9.08 Million |
| 2017 | 10.84% | 7.47% | 0.97x | 1.49x | NT$7.01 Million |
| 2018 | 11.79% | 11.30% | 0.77x | 1.36x | NT$24.12 Million |
| 2019 | 11.87% | 10.25% | 0.82x | 1.41x | NT$25.37 Million |
| 2020 | 2.25% | 1.78% | 0.51x | 2.48x | NT$-96.10 Million |
| 2021 | 5.40% | 5.49% | 0.64x | 1.53x | NT$-88.90 Million |
| 2022 | 9.08% | 7.60% | 0.78x | 1.54x | NT$-18.37 Million |
| 2023 | 4.04% | 4.10% | 0.58x | 1.69x | NT$-113.89 Million |
| 2024 | 6.48% | 6.14% | 0.63x | 1.67x | NT$-67.69 Million |
Industry Comparison
This section compares Panion & BF Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,081,735,222
- Average return on equity (ROE) among peers: 7.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Panion & BF Biotech Inc (1760) | NT$1.90 Billion | 1.74% | 0.64x | $122.27 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |